KR102395737B1 - Plk-4 억제제의 염 및 결정체들 - Google Patents

Plk-4 억제제의 염 및 결정체들 Download PDF

Info

Publication number
KR102395737B1
KR102395737B1 KR1020217036751A KR20217036751A KR102395737B1 KR 102395737 B1 KR102395737 B1 KR 102395737B1 KR 1020217036751 A KR1020217036751 A KR 1020217036751A KR 20217036751 A KR20217036751 A KR 20217036751A KR 102395737 B1 KR102395737 B1 KR 102395737B1
Authority
KR
South Korea
Prior art keywords
compound
cancer
fumarate
maleate
crystalline form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217036751A
Other languages
English (en)
Korean (ko)
Other versions
KR20210137251A (ko
Inventor
피터 브렌트 샘슨
미클로시 페헤르
하인즈 더블유 폴스
Original Assignee
유니버시티 헬스 네트워크
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유니버시티 헬스 네트워크 filed Critical 유니버시티 헬스 네트워크
Priority to KR1020227015022A priority Critical patent/KR20220063299A/ko
Publication of KR20210137251A publication Critical patent/KR20210137251A/ko
Application granted granted Critical
Publication of KR102395737B1 publication Critical patent/KR102395737B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020217036751A 2013-10-18 2014-10-17 Plk-4 억제제의 염 및 결정체들 Active KR102395737B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227015022A KR20220063299A (ko) 2013-10-18 2014-10-17 Plk-4 억제제의 염 및 결정체들

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361892564P 2013-10-18 2013-10-18
US61/892,564 2013-10-18
KR1020167012155A KR20160070106A (ko) 2013-10-18 2014-10-17 Plk-4 억제제의 염 및 결정체들
PCT/CA2014/051001 WO2015054793A1 (en) 2013-10-18 2014-10-17 Salt and crystal forms of plk-4 inhibitor

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020167012155A Division KR20160070106A (ko) 2013-10-18 2014-10-17 Plk-4 억제제의 염 및 결정체들

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227015022A Division KR20220063299A (ko) 2013-10-18 2014-10-17 Plk-4 억제제의 염 및 결정체들

Publications (2)

Publication Number Publication Date
KR20210137251A KR20210137251A (ko) 2021-11-17
KR102395737B1 true KR102395737B1 (ko) 2022-05-10

Family

ID=52827507

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020227015022A Ceased KR20220063299A (ko) 2013-10-18 2014-10-17 Plk-4 억제제의 염 및 결정체들
KR1020167012155A Ceased KR20160070106A (ko) 2013-10-18 2014-10-17 Plk-4 억제제의 염 및 결정체들
KR1020217036751A Active KR102395737B1 (ko) 2013-10-18 2014-10-17 Plk-4 억제제의 염 및 결정체들

Family Applications Before (2)

Application Number Title Priority Date Filing Date
KR1020227015022A Ceased KR20220063299A (ko) 2013-10-18 2014-10-17 Plk-4 억제제의 염 및 결정체들
KR1020167012155A Ceased KR20160070106A (ko) 2013-10-18 2014-10-17 Plk-4 억제제의 염 및 결정체들

Country Status (27)

Country Link
US (5) US9884855B2 (enExample)
EP (1) EP3057965B1 (enExample)
JP (1) JP6492072B2 (enExample)
KR (3) KR20220063299A (enExample)
CN (2) CN105764899B (enExample)
AU (1) AU2014336929B9 (enExample)
CA (1) CA2926845C (enExample)
CY (1) CY1121484T1 (enExample)
DK (1) DK3057965T3 (enExample)
EA (1) EA031569B1 (enExample)
ES (1) ES2718603T3 (enExample)
HR (1) HRP20190564T1 (enExample)
HU (1) HUE043194T2 (enExample)
IL (1) IL245038B (enExample)
LT (1) LT3057965T (enExample)
ME (1) ME03377B (enExample)
MX (1) MX359069B (enExample)
NZ (1) NZ718744A (enExample)
PL (1) PL3057965T3 (enExample)
PT (1) PT3057965T (enExample)
RS (1) RS58413B1 (enExample)
SG (1) SG11201602783SA (enExample)
SI (1) SI3057965T1 (enExample)
SM (1) SMT201900124T1 (enExample)
TR (1) TR201902875T4 (enExample)
TW (1) TWI659952B (enExample)
WO (1) WO2015054793A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2465971T3 (es) 2009-04-06 2014-06-09 University Health Network Inhibidores de quinasa y método para tratar cáncer con los mismos
NZ602350A (en) 2010-04-06 2014-05-30 Univ Health Network Kinase inhibitors and method of treating cancer with same
SI3057965T1 (sl) 2013-10-18 2019-04-30 University Health Network Sol in kristalne oblike inhibitorja PLK-4
CA3074876A1 (en) * 2017-09-08 2019-03-14 University Health Network Combination therapies for inhibition of polo-like kinase 4
BR112021021106A2 (pt) * 2019-04-24 2021-12-14 Univ Health Network Forma cristalina s4 do inibidor plk4 fumarato (ir,2s)-(e)-2-(3-(4-((cis-2,6-dimetilmorfolino)metil)estiril)-1h-imidazol-6-il)-5'-metoxiespiro[ciclopropano-1,3'-indolin]-2'ona
MX2022006910A (es) * 2019-12-06 2022-11-09 Univ Health Network Tratamiento para la leucemia mieloide aguda o para el síndrome mielodisplásico.
US20240270722A1 (en) 2021-05-11 2024-08-15 Oric Pharmaceuticals, Inc. Polo like kinase 4 inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2483323A (en) * 1945-08-01 1949-09-27 Kay Fries Chemicals Inc Method of preparing phenyl ethyl alcohol
US7205328B2 (en) 2002-10-21 2007-04-17 Irm Llc Oxindoles with anti-HIV activity
DE102005005395A1 (de) * 2005-02-03 2006-08-10 Schering Aktiengesellschaft Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel
GB0606234D0 (en) * 2006-03-29 2006-05-10 Pliva Istrazivanje I Razvoj D Pharmaceutically acceptable salts and polymorphic forms
EP2148740A4 (en) * 2007-03-23 2012-10-31 Agency Science Tech & Res Palladium catalysts
EP2564850B1 (en) * 2007-09-25 2014-08-13 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
AU2008340991B2 (en) 2007-12-21 2012-02-23 University Health Network Indazolyl, benzimidazolyl, benzotriazolyl substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer
ES2465971T3 (es) 2009-04-06 2014-06-09 University Health Network Inhibidores de quinasa y método para tratar cáncer con los mismos
WO2010125004A1 (en) 2009-04-29 2010-11-04 Nerviano Medical Sciences S.R.L. Cdk inhibitor salts
NZ602350A (en) * 2010-04-06 2014-05-30 Univ Health Network Kinase inhibitors and method of treating cancer with same
EP2588110B1 (en) 2010-07-02 2018-10-17 University Health Network Methods of targeting pten mutant diseases and compositions therefor
WO2012048411A1 (en) * 2010-10-13 2012-04-19 University Health Network Plk-4 inhibitors and method of treating cancer with same
KR20130105675A (ko) * 2010-11-25 2013-09-25 라티오팜 게엠베하 아파티닙의 신규 염 및 다형
US9580390B2 (en) * 2011-10-12 2017-02-28 University Health Network Indazole compounds as kinase inhibitors and method of treating cancer with same
SI3057965T1 (sl) 2013-10-18 2019-04-30 University Health Network Sol in kristalne oblike inhibitorja PLK-4
CA2927612C (en) 2013-10-18 2022-08-30 University Health Network Treatment for pancreatic cancer

Also Published As

Publication number Publication date
CN105764899B (zh) 2021-06-01
KR20210137251A (ko) 2021-11-17
KR20160070106A (ko) 2016-06-17
RS58413B1 (sr) 2019-04-30
SI3057965T1 (sl) 2019-04-30
ES2718603T3 (es) 2019-07-03
US20160264559A1 (en) 2016-09-15
NZ718744A (en) 2021-07-30
TWI659952B (zh) 2019-05-21
JP6492072B2 (ja) 2019-03-27
EA201690755A1 (ru) 2016-09-30
JP2016537326A (ja) 2016-12-01
US20210269428A1 (en) 2021-09-02
HUE043194T2 (hu) 2019-08-28
TW201609717A (zh) 2016-03-16
CA2926845C (en) 2023-06-13
SMT201900124T1 (it) 2019-05-10
EP3057965A4 (en) 2017-05-24
US10919886B2 (en) 2021-02-16
CN105764899A (zh) 2016-07-13
CA2926845A1 (en) 2015-04-23
HRP20190564T1 (hr) 2019-05-17
LT3057965T (lt) 2019-03-12
US11667627B2 (en) 2023-06-06
IL245038A0 (en) 2016-05-31
US10392374B2 (en) 2019-08-27
SG11201602783SA (en) 2016-05-30
AU2014336929B2 (en) 2018-11-22
US20200140428A1 (en) 2020-05-07
AU2014336929B9 (en) 2019-03-21
EA031569B1 (ru) 2019-01-31
IL245038B (en) 2019-11-28
TR201902875T4 (tr) 2019-03-21
CN113248486A (zh) 2021-08-13
WO2015054793A1 (en) 2015-04-23
DK3057965T3 (en) 2019-04-01
US20190248775A1 (en) 2019-08-15
US9884855B2 (en) 2018-02-06
EP3057965A1 (en) 2016-08-24
KR20220063299A (ko) 2022-05-17
CY1121484T1 (el) 2020-05-29
EP3057965B1 (en) 2019-01-02
MX2016004963A (es) 2016-06-28
PL3057965T3 (pl) 2019-08-30
US20180155335A1 (en) 2018-06-07
ME03377B (me) 2020-01-20
MX359069B (es) 2018-09-12
PT3057965T (pt) 2019-04-23
US10472353B2 (en) 2019-11-12

Similar Documents

Publication Publication Date Title
KR102395737B1 (ko) Plk-4 억제제의 염 및 결정체들
AU2014336929A1 (en) Salt and crystal forms of PLK-4 inhibitor
US11104681B2 (en) Solid forms of TTK inhibitor
HK1227404B (en) Salt and crystal forms of plk-4 inhibitor
HK1227404A1 (en) Salt and crystal forms of plk-4 inhibitor
EA044843B1 (ru) Кристаллическая форма ингибитора plk4
HK40007702A (en) Solid forms of ttk inhibitor
HK40007702B (en) Solid forms of ttk inhibitor

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

K11 Ip right revival requested

Free format text: ST27 STATUS EVENT CODE: A-6-4-K10-K11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

K11-X000 Ip right revival requested

St.27 status event code: A-6-4-K10-K11-oth-X000

K12 Request for ip right revival rejected

Free format text: ST27 STATUS EVENT CODE: A-6-4-K10-K12-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

K12-X000 Request for ip right revival rejected

St.27 status event code: A-6-4-K10-K12-oth-X000